MDM2 and neoplasm: Data from cancer cell lines, a cholera mouse model, and patients with melanoma suggest that MDM2 inhibitor-mediated pharmacological p53 reactivation triggers the ERV-dsRNA-IFN pathway in tumor cells, thereby altering the TME to a therapeutically responsive phenotype and triggering tumor immune surveillance [90].